Dec 5 (Reuters) - Replimune Group said on Tuesday its experimental drug to treat a common form of skin cancer did not meet the main goals in a late-stage study. (Reporting by Mariam Sunny in Bengaluru; Editing by Arun Koyyur)
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
6.44 USD | -4.17% | +0.31% | -23.72% |
May. 16 | Replimune Group, Inc. Reports Earnings Results for the Full Year Ended March 31, 2024 | CI |
Apr. 08 | Replimune Group Provides Interim Results for Skin Cancer Therapy | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-23.72% | 413M | |
+33.26% | 50.85B | |
+0.09% | 42.82B | |
+49.62% | 42.03B | |
-4.96% | 29.55B | |
+11.07% | 26.11B | |
-22.05% | 19.13B | |
+8.51% | 13.05B | |
+27.65% | 12.16B | |
+24.65% | 12.08B |
- Stock Market
- Equities
- REPL Stock
- News Replimune Group, Inc.
- Replimune's skin cancer drug fails in late-stage study